ArticleHaematologica2021

An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study.

Hanny Al-Samkari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.